help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfeiffer, A.
Right arrow Articles by Brantl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfeiffer, A.
Right arrow Articles by Brantl, V.

Journal of Clinical Endocrinology & Metabolism, Vol 62, 181-185, Copyright © 1986 by Endocrine Society

ARTICLES

Anterior pituitary hormone responses to a kappa-opioid agonist in man

A Pfeiffer, S Braun, K Mann, HD Meyer and V Brantl

The present study was designed to investigate pituitary hormone responses to a kappa-opiate receptor agonist in man. Normal men were given the racemic benzomorphan kappa-agonist MR 2033 or its levorotatory isomer MR 2034 iv. Plasma levels of PRL and GH markedly increased after injection of 3.5 micrograms/kg MR 2033 or 1.9 or 3.8 micrograms/kg MR 2034. These effects of MR 2033 were blocked by the opiate antagonist naloxone (10 mg), thereby demonstrating their mediation by opiate receptors. The kappa-agonist did not change plasma levels of LH and FSH. The secretion of TSH was significantly suppressed by MR 2033 and MR 2034, but this action was not antagonized by pretreatment with naloxone. The suppression of plasma TSH was, however, stereospecific since the (+)-isomer, MR 2035, did not affect TSH secretion. These data indicate that kappa-opiate receptors are located on neuronal pathways regulating GH, TSH, and PRL secretion. The pattern of pituitary responses elicited by the kappa-agonist differs from that of mu-opioid agonists, indicating differential endocrine functions for the endogenous agonists.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
R. M. Sapolsky, L. M. Romero, and A. U. Munck
How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions
Endocr. Rev., February 1, 2000; 21(1): 55 - 89.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Hangaard, M. Andersen, E. Grodum, O. Koldkjær, and C. Hagen
The Effects of Endogenous Opioids and Cortisol on Thyrotropin and Prolactin Secretion in Patients with Addison's Disease
J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1595 - 1601.
[Abstract] [Full Text]

Home page
 ScienceHome page
A Pfeiffer, V Brantl, A Herz, and H. Emrich
Psychotomimesis mediated by kappa opiate receptors
Science, August 15, 1986; 233(4765): 774 - 776.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society